Your browser doesn't support javascript.
loading
Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL.
Awasthi, Rakesh; Pacaud, Lida; Waldron, Edward; Tam, Constantine S; Jäger, Ulrich; Borchmann, Peter; Jaglowski, Samantha; Foley, Stephen Ronan; van Besien, Koen; Wagner-Johnston, Nina D; Kersten, Marie José; Schuster, Stephen J; Salles, Gilles; Maziarz, Richard T; Anak, Özlem; Del Corral, Christopher; Chu, Jufen; Gershgorin, Irina; Pruteanu-Malinici, Iulian; Chakraborty, Abhijit; Mueller, Karen Thudium; Waller, Edmund K.
Afiliação
  • Awasthi R; Novartis Institutes for BioMedical Research, East Hanover, NJ.
  • Pacaud L; Novartis Pharmaceuticals Corporation, East Hanover, NJ.
  • Waldron E; Novartis Pharmaceuticals Corporation, East Hanover, NJ.
  • Tam CS; Hematology Department, Peter MacCallum Cancer Center, University of Melbourne, Melbourne, Australia.
  • Jäger U; Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Borchmann P; Department of Hematology and Oncology, University Hospital of Cologne, Cologne, Germany.
  • Jaglowski S; The James Cancer Hospital and Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Foley SR; Juravinski Hospital and Cancer Center, McMaster University, Hamilton, ON, Canada.
  • van Besien K; Division of Hematology and Oncology, Weill Cornell Medicine and New York-Presbyterian Hospital, New York, NY.
  • Wagner-Johnston ND; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD.
  • Kersten MJ; Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Schuster SJ; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
  • Salles G; Department of Hematology, CHU Lyon-Sud Hospital, Hospices Civils de Lyon, Lyon, France.
  • Maziarz RT; Center for Hematologic Malignancies, Oregon Health & Science University Knight Cancer Institute, Portland, OR; and.
  • Anak Ö; Novartis Pharmaceuticals Corporation, East Hanover, NJ.
  • Del Corral C; Novartis Pharmaceuticals Corporation, East Hanover, NJ.
  • Chu J; Novartis Pharmaceuticals Corporation, East Hanover, NJ.
  • Gershgorin I; Novartis Pharmaceuticals Corporation, East Hanover, NJ.
  • Pruteanu-Malinici I; Novartis Institutes for BioMedical Research, East Hanover, NJ.
  • Chakraborty A; Novartis Institutes for BioMedical Research, East Hanover, NJ.
  • Mueller KT; Novartis Institutes for BioMedical Research, East Hanover, NJ.
  • Waller EK; Bone Marrow and Stem Cell Transplant Center, Winship Cancer Institute of Emory University, Atlanta, GA.
Blood Adv ; 4(3): 560-572, 2020 02 11.
Article em En | MEDLINE | ID: mdl-32045475
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores de Antígenos de Linfócitos T / Linfoma Difuso de Grandes Células B Tipo de estudo: Prognostic_studies Limite: Adult / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores de Antígenos de Linfócitos T / Linfoma Difuso de Grandes Células B Tipo de estudo: Prognostic_studies Limite: Adult / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article